Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Salesforce Shares Face Pressure Despite Solid Fundamentals

Andreas Sommer by Andreas Sommer
September 26, 2025
in AI & Quantum Computing, Analysis, Earnings, Tech & Software
0
Salesforce Stock
0
SHARES
124
VIEWS
Share on FacebookShare on Twitter

Salesforce finds itself navigating a challenging market environment. The customer relationship management leader recently posted impressive quarterly figures, including a 10% revenue increase, yet its stock continues a persistent downward trajectory. The central concern among investors is the apparent delay in monetizing the company’s multi-billion dollar artificial intelligence initiatives. While the long-term potential is widely acknowledged, the market is growing impatient for tangible financial results from the AI push.

Strong Earnings Overshadowed by Cautious Outlook

The paradox for Salesforce is stark. For the second quarter of its 2026 fiscal year, the company announced robust performance, surpassing expectations with revenues of $10.2 billion. Its adjusted earnings per share came in at $2.91, notably higher than most analyst forecasts. Despite these strong fundamentals, the equity has been under significant selling pressure.

This negative trend continued recently, with shares dropping another 2% in a single Thursday session. Since the start of the year, the stock has declined by a substantial 27.5 percent. The primary trigger for the latest sell-off was the company’s guidance for the upcoming third quarter. Salesforce projected revenues in the range of $10.24 to $10.29 billion. The midpoint of this forecast fell short of the more optimistic numbers anticipated on Wall Street, causing a sharp decline in after-hours trading.

The AI Monetization Question

The core issue fueling investor skepticism is the pace at which Salesforce’s highly publicized AI investments are contributing to the bottom line. CEO Marc Benioff has been a vocal proponent of the technology’s transformative impact. However, specific revenue contributions from new AI-driven products, such as the “Agentforce” platform, have yet to materialize in a significant way within the company’s financial statements. The subdued forecast has intensified doubts about the timeline for AI to become a major growth driver.

Should investors sell immediately? Or is it worth buying Salesforce?

A Divided Analytical Community

Market experts remain divided in their assessment of Salesforce’s prospects. On one hand, analysts like Patrick Walravens from Citizens JMP maintain a bullish stance, recently reaffirming a “Buy” rating with a price target of $430. This optimism is rooted in the belief in the vast potential embedded within Salesforce’s AI ecosystem.

Conversely, other firms advocate for caution. Macquarie, for instance, holds a “Neutral” rating with a more conservative price target of $250. The overall analyst consensus, which currently comprises 30 “Buy” recommendations, eight “Hold” ratings, and a single “Sell” recommendation, points to a “moderate Buy” sentiment.

The fundamental challenge for investors remains unchanged. The long-term opportunity presented by AI is not in dispute, but the short-term execution appears to be lagging behind the ambitious expectations set by the company. The market is now forced to weigh whether the current price represents a buying opportunity for a long-term AI bet or if expectations need to be reset for the foreseeable future.

Ad

Salesforce Stock: Buy or Sell?! New Salesforce Analysis from March 25 delivers the answer:

The latest Salesforce figures speak for themselves: Urgent action needed for Salesforce investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Salesforce: Buy or sell? Read more here...

Tags: Salesforce
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

March 25, 2026
SOXX ETF Stock
Commodities

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock
Analysis

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Next Post
Meta Stock

A Day of Extremes for Meta: Regulatory Storm Clouds as Threads Overtakes X

Pfizer Stock

Pfizer Bets Billions on Obesity Market Entry with Metsera Acquisition

UPS Stock

UPS Shares Plunge to Lowest Point in a Year

Recommended

Lockheed Martin Stock

Defense Giant Lockheed Martin Secures Billions in New Military Contracts

6 months ago
OKE stock news

Amalgamated Bank Increases Stake in CF Industries as Market Opinions Vary

3 years ago
IBM Stock

IBM’s AI Windfall Fails to Impress Stock Market

7 months ago
Blackstonecured Lending Fund Stock

Blackstone BDC Insider Purchase Defies Analyst Downgrades

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Figma Embraces Third-Party AI to Power Its Design Ecosystem

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

Evolent Health Bets on AI Leadership Amid Share Price Decline

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Trending

Gossamer Bio Stock
Analysis

Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026

by Kennethcix
March 25, 2026
0

The future of Gossamer Bio hinges on a critical regulatory discussion scheduled for June 2026. The biopharmaceutical...

SOXX ETF Stock

Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns

March 25, 2026
Fair Isaac Stock

Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

March 25, 2026
Figma Stock

Figma Embraces Third-Party AI to Power Its Design Ecosystem

March 25, 2026
BioNano Genomics Stock

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Gossamer Bio’s Pivotal FDA Meeting Looms in June 2026
  • Semiconductor Sector Faces Supply Chain Strain Amid Helium Shortage Concerns
  • Regulatory Scrutiny and Price Wars Threaten Fair Isaac’s Dominance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com